{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:39Z","timestamp":1787635479652,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004761","name":"the Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2022JJ40002"],"award-info":[{"award-number":["2022JJ40002"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Key Research and Development Program","award":["2020BCB013"],"award-info":[{"award-number":["2020BCB013"]}]},{"name":"Clinic Research Foundation of Aier Eye Hospital Group","award":["AIM2301D06"],"award-info":[{"award-number":["AIM2301D06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40123-025-01257-1","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:04:44Z","timestamp":1760364284000},"page":"3047-3057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resolution of Near-Work-Related Effects, Accommodation, and Binocular Vision Changes of 0.05% Atropine After 1 Year: Secondary Analysis of a Prospective Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Wei","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexiang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-557X","authenticated-orcid":false,"given":"Xiaoning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"4","key":"1257_CR1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. https:\/\/doi.org\/10.1167\/iovs.61.4.49. (Apr 9).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"1257_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/OPX.0000000000000516","volume":"92","author":"CW Pan","year":"2015","unstructured":"Pan CW, Dirani M, Cheng CY, Wong TY, Saw SM. The age-specific prevalence of myopia in Asia: a meta-analysis. Optom Vis Sci. 2015;92(3):258\u201366. https:\/\/doi.org\/10.1097\/OPX.0000000000000516.","journal-title":"Optom Vis Sci"},{"key":"1257_CR3","doi-asserted-by":"publisher","unstructured":"Pan W, Saw S-M, Wong TY, Morgan I, Yang Z, Lan W. Prevalence and temporal trends in myopia and high myopia children in China: a systematic review and meta-analysis with projections from 2020 to 2050. Lancet Reg Health\u2013Western Pac. 2025;55:101484. https:\/\/doi.org\/10.1016\/j.lanwpc.2025.101484","DOI":"10.1016\/j.lanwpc.2025.101484"},{"key":"1257_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-024-00887-1","author":"W Pan","year":"2024","unstructured":"Pan W, Lan W. The current and future landscape of the childhood myopia epidemic in China-a review. Ophthalmol Ther. 2024. https:\/\/doi.org\/10.1007\/s40123-024-00887-1.","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"1257_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/opo.12052","volume":"33","author":"NA McBrien","year":"2013","unstructured":"McBrien NA, Stell WK, Carr B. How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt. 2013;33(3):373\u20138. https:\/\/doi.org\/10.1111\/opo.12052.","journal-title":"Ophthalmic Physiol Opt"},{"key":"1257_CR6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.5.3","author":"IG Morgan","year":"2021","unstructured":"Morgan IG, Wu P-C, Ostrin LA, et al. IMI risk factors for myopia. Invest Ophthalmol Vis Sci. 2021. https:\/\/doi.org\/10.1167\/iovs.62.5.3.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1257_CR7","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1167\/iovs.17-22562","volume":"59","author":"BJ Carr","year":"2018","unstructured":"Carr BJ, Mihara K, Ramachandran R, et al. Myopia-inhibiting concentrations of muscarinic receptor antagonists block activation of Alpha2A-adrenoceptors in vitro. Invest Ophthalmol Vis Sci. 2018;59(7):2778\u201391. https:\/\/doi.org\/10.1167\/iovs.17-22562.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"1257_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/cxo.12871","volume":"102","author":"BJ Carr","year":"2019","unstructured":"Carr BJ, Nguyen CT, Stell WK. Alpha(2) -adrenoceptor agonists inhibit form-deprivation myopia in the chick. Clin Exp Optom. 2019;102(4):418\u201325. https:\/\/doi.org\/10.1111\/cxo.12871.","journal-title":"Clin Exp Optom"},{"issue":"7","key":"1257_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/0042-6989(95)00191-3","volume":"36","author":"KL Schmid","year":"1996","unstructured":"Schmid KL, Wildsoet CF. Effects on the compensatory responses to positive and negative lenses of intermittent lens wear and ciliary nerve section in chicks. Vis Res. 1996;36(7):1023\u201336. https:\/\/doi.org\/10.1016\/0042-6989(95)00191-3.","journal-title":"Vis Res"},{"issue":"1","key":"1257_CR10","first-page":"205","volume":"34","author":"NA McBrien","year":"1993","unstructured":"McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci. 1993;34(1):205\u201315.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"1257_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/bjophthalmol-2019-315258","volume":"104","author":"L Wen","year":"2020","unstructured":"Wen L, Cao Y, Cheng Q, et al. Objectively measured near work, outdoor exposure and myopia in children. Br J Ophthalmol. 2020;104(11):1542\u20137. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315258.","journal-title":"Br J Ophthalmol"},{"key":"1257_CR12","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.5.4","author":"NS Logan","year":"2021","unstructured":"Logan NS, Radhakrishnan H, Cruickshank FE, et al. Imi accommodation and binocular vision in myopia development and progression. Invest Ophthalmol Vis Sci. 2021. https:\/\/doi.org\/10.1167\/iovs.62.5.4.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1257_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Q Gong","year":"2017","unstructured":"Gong Q, Janowski M, Luo M, et al. Efficacy and adverse effects of atropine in childhood myopia: a meta-analysis. JAMA Ophthalmol. 2017;135(6):624\u201330. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1091.","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"1257_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and safety of 8 atropine concentrations for myopia control in children: a network meta-analysis. Ophthalmology. 2022;129(3):322\u201333. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.016.","journal-title":"Ophthalmology"},{"issue":"2","key":"1257_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua W-H, Cheung Y-B, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the treatment of myopia 2). Ophthalmology. 2012;119(2):347\u201354. https:\/\/doi.org\/10.1016\/j.ophtha.2011.07.031.","journal-title":"Ophthalmology"},{"issue":"5","key":"1257_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/apo.0000000000000256","volume":"8","author":"FF Li","year":"2019","unstructured":"Li FF, Yam JC. Low-concentration atropine eye drops for myopia progression. Asia-Pac J Ophthalmol. 2019;8(5):360\u20135. https:\/\/doi.org\/10.1097\/apo.0000000000000256.","journal-title":"Asia-Pac J Ophthalmol"},{"issue":"7","key":"1257_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology. 2020;127(7):910\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.011.","journal-title":"Ophthalmology"},{"issue":"3","key":"1257_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","volume":"129","author":"JC Yam","year":"2022","unstructured":"Yam JC, Zhang XJ, Zhang Y, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology. 2022;129(3):308\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.002.","journal-title":"Ophthalmology"},{"issue":"11","key":"1257_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138(11):1178\u201384. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3820.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1257_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01746-w","volume":"20","author":"C Zhao","year":"2020","unstructured":"Zhao C, Cai C, Ding Q, Dai H. Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis. BMC Ophthalmol. 2020;20(1):478. https:\/\/doi.org\/10.1186\/s12886-020-01746-w.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"1257_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4103\/ijo.IJO_1243_19","volume":"68","author":"M Kothari","year":"2020","unstructured":"Kothari M, Modak M, Khan H, Jahan S, Solanki M, Rathod V. Convergence excess consecutive esotropia associated with 0.01% atropine eye drops usage in patients operated for intermittent exotropia. Indian J Ophthalmol. 2020;68(4):653\u20136. https:\/\/doi.org\/10.4103\/ijo.IJO_1243_19.","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"1257_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-024-00395-0","volume":"11","author":"Y Yang","year":"2024","unstructured":"Yang Y, Xue M, Hao J, et al. Frequency-dependent effects of 0.05% atropine eyedrops on myopia progression and peripheral defocus: a prospective study. Eye Vis. 2024;11(1):26. https:\/\/doi.org\/10.1186\/s40662-024-00395-0.","journal-title":"Eye Vis"},{"issue":"6","key":"1257_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.4103\/0301-4738.126990","volume":"62","author":"H Momeni-Moghaddam","year":"2014","unstructured":"Momeni-Moghaddam H, Kundart J, Askarizadeh F. Comparing measurement techniques of accommodative amplitudes. Indian J Ophthalmol. 2014;62(6):683\u20137. https:\/\/doi.org\/10.4103\/0301-4738.126990.","journal-title":"Indian J Ophthalmol"},{"issue":"7","key":"1257_CR24","doi-asserted-by":"publisher","first-page":"e1222","DOI":"10.1111\/aos.14785","volume":"99","author":"L Wen","year":"2021","unstructured":"Wen L, Cheng Q, Cao Y, et al. The clouclip, a wearable device for measuring near-work and outdoor time: validation and comparison of objective measures with questionnaire estimates. Acta Ophthalmol. 2021;99(7):e1222\u201335. https:\/\/doi.org\/10.1111\/aos.14785.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1257_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"key":"1257_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.808440","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Zhang L, Tian H, et al. Effect of 0.01% atropine on accommodation in myopic teenagers. Front Pharmacol. 2022;13:808440. https:\/\/doi.org\/10.3389\/fphar.2022.808440.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1257_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/OPX.0000000000002031","volume":"100","author":"RE Breliant","year":"2023","unstructured":"Breliant RE, Pang Y, Bandstra A, Kattouf V. Effect of low-dose atropine on binocular vision and accommodation in children aged 6 to 17 years. Optom Vis Sci. 2023;100(8):550\u20136. https:\/\/doi.org\/10.1097\/OPX.0000000000002031.","journal-title":"Optom Vis Sci"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01257-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01257-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:58:45Z","timestamp":1761908325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01257-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01257-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wei Pan, Haoran Wu, Yao Tang, Yuanfang Yang, Qinglin Xu, Zhiwei Luo, Ziqi Hu, Wenyu Gao, Lijun Hou, Yuexiang Deng, Zhikuan Yang, and Xiaoning Li confirm that they have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study adhered to the principles of the Declaration of Helsinki, and the study protocol received approval from the ethics committee of the Changsha Aier Eye Hospital, with all procedures conducted in accordance with the former. The study also complied with Good Clinical Practice standard. Verbal assent was obtained from participating children, and written informed consent was obtained from their parents or guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}